Diasorin S.p.a. · MIL:DIA
Diasorin — 9M 2024 Earnings Presentation
18 slides from Diasorin's earnings presentation, Nov 5, 2024
Slide 1: 9M 2024 Results
9M 2024 RESULTS November 5, 2024
Slide 2: Disclaimer
DISCLAIMER No distribution of this Presentation. This Presentation is being furnished to you In General. This disclaimer applies to this presentation and any oral solely for your information and may not be reproduced, in whole or in part, or comments of any person presenting it. This document, taken
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Change Data in €/mln Q3 2024 9M 2024 @ current @ CER @ current @ CER Revenues 287 +6% +7% 876 +4% +4% Immunodiagnostics ex-COVID 193 +10% +11% 583 +10% +10% Molecular Diagnostics ex-COVID 46 +5% +6% 147 +4% +5% Licensed Technologies1 42 +7% +8% 126 +1% +1% COVID 6 -45% -4
Slide 6: 9M 2024 Key Facts
9M 2024 KEY FACTS PRODUCT & BUSINESS DEVELOPMENT IMMUNODIAGNOSTICS • LIAISON® LymeDetect® submitted to the U.S. FDA • LIAISON® Streptococcus pneumoniae Ag launched in all countries accepting the CE Mark MOLECULAR DIAGNOSTICS SINGLE-LOW PLEX • Execution of the project to sunset the ARIES platform and
Slide 7: Managerial Outlook on Q3 and 9M 2024 Revenues
MANAGERIAL OUTLOOK ON Q3 AND 9M 2024 REVENUES Q3 2024 Group revenues (data in €/mln) 9M 2024 Group revenues (data in €/mln) Data @CUR Data @CER Data @CUR Data @CER +6% +7% +4% +4% 876 879 287 289 846 846 270 270 20 20 6 6 46 126 46 126 COVID sales 11 42 11 42 125 125 39 39 147 147 46 47 141 141 Lice
Slide 8: Q3 and 9M 2024 Revenues by Geography
Q3 AND 9M 2024 REVENUES BY GEOGRAPHY Q3 2023 Q3 2024 Rest of the World Rest of the World 17% 16% North America North America Direct Direct 50% 51% Europe Direct Europe Direct 33% 33% 9M 2023 9M 2024 Rest of the World Rest of the World 17% 15% North America North America Direct Direct 49% 50% Europe
Slide 9: Q3 and 9M 2024 Profitability Profile
Q3 AND 9M 2024 PROFITABILITY PROFILE (data in €/mln @ current exchange rates) 33% 33% 270 287 88 94 Net Revenues 9M 2024 Adjusted2 EBITDA is better than last year by €15m or 5%, whereas Q3’24 improvement accelerates to 7%. Adjusted EBITDA Adjusted2 EBITDA Q3 2023 Q3 2024 Margin, both in the quarter
Slide 10: FY 2024 Company Guidance
FY 2024 COMPANY GUIDANCE
Slide 11: Company Raises FY 2024 Revenue Guidance
COMPANY RAISES FY 2024 REVENUE GUIDANCE NEW FY 2024 COMPANY GUIDANCE (@CER) Ex-COVID revenues: approx. +7% (COVID sales equal to ~ 30 €/mln) Adjusted2 EBITDA Margin: ~ 33% PREVIOUS FY 2024 COMPANY GUIDANCE (@CER) Ex-COVID revenues: +6% / +7% (COVID sales equal to ~ 30 €/mln) Adjusted2 EBITDA Margin:
Slide 12: Financial Schemes
FINANCIAL SCHEMES
Slide 13: Income Statement
INCOME STATEMENT Q3 9 months Amounts in millions of euros 2023 2024 2023 2024 Net Revenues 270 287 846 876 Cost of sales (102) (99) (300) (299) Gross profit 167 188 546 578 62% 65% 65% 66% Sales and marketing expenses (70) (70) (212) (211) Research and development costs (22) (22) (68) (65) General a
Slide 14: Balance Sheet
BALANCE SHEET Amounts in millions of euros 12/31/2023 09/30/2024 Change Goodwill and intangibles assets 1,925 1,901 -23 Property, plant and equipment 256 258 +2 Other non-current assets 35 34 -1 Net working capital 369 364 -4 Other non-current liabilities (270) (263) +8 Net Invested Capital 2,314 2,
Slide 15: Cash Flow Statement
CASH FLOW STATEMENT Q3 9 months Amounts in millions of euros 2023 2024 2023 2024 Cash and cash equivalents at the beginning of the period 256 170 242 280 Cash provided by operating activities 80 131 226 286 Cash provided/(used) in investing activities (49) (26) 20 (37) Cash provided/(used) in financ
Slide 16: 9M 2024 Reconciliation to Consolidated Financial Statements
9M 2024 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of Euro Gross profit EBITDA EBIT Net result IFRS Financial Statements Measures 578 289 193 141 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 3 3 3 Dep
Slide 17: 9M 2023 Reconciliation to Consolidated Financial Statements
9M 2023 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of Euro Gross profit EBITDA EBIT Net result IFRS Financial Statements Measures 546 260 156 112 % on Revenues 65% 31% 18% 13% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 6 6 6 Dep
Slide 18: Slide 18